Navigation Links
BioMedix™ Now Exclusive Industry Distributor of the APMA Coding Resource Center
Date:1/20/2011

SAINT PAUL, Minn., Jan. 20, 2011 /PRNewswire/ -- BioMedix™ has announced that it has initiated an exclusive partnership with the American Podiatric Medical Association (APMA) to become the sole distributor of the APMA Coding Resource Center (CRC) online coding and reimbursement resource which includes foot, ankle and leg-relevant CPT©, ICD-9 and HCPCS Level II codes that can be fully integrated with BioMedix™ TRAKnet™ DPM Practice Management Solutions. This exciting partnership provides the most accessible and cost-effective coding information for podiatric practices.

"APMA highly values its strong relationship with our Corporate Partner BioMedix™", said Glenn Gastwirth, DPM, APMA executive director and CEO. "We believe that BioMedix™ is the ideal match as the exclusive distributor of APMA's CRC because of its understanding of the technology needs of podiatric physicians, commitment to customer service and uncompromising integrity. This relationship allows APMA, which owns CRC, to continue to maintain complete control over the content of the CRC while partnering with a trusted company to handle the distribution."

CRC users can look up codes, check Medicare National Correct Coding Initiative (CCI) edits, review carrier Local Coverage Determinations (LCDs) and get the latest coding and reimbursement information and articles from any location with an Internet connection. BioMedix™ products with CRC integration bring real-time coding information updates into podiatric practices on demand, providing a single source of coding information that is both convenient and economical. This valuable resource also includes DME and Medicare references, coverage guidelines and the complete searchable archive of APMA Coding newsletter articles. The cost of the one-year subscription to APMA Coding Resource Center is less than the cost of purchasing CPT, ICD-9-CM and HCPCS alone.

"BioMedix™ is continually striving to support the podiatric profession with the most beneficial and cost-effective products and services," said John Romans, President & CEO of BioMedix™.
"Our partnership with APMA and our exclusive distribution of the Coding Resource Center is an exciting way to add additional value to BioMedix™ customers and the podiatric physician community."

About BioMedix™

BioMedix™ provides the only integrated suite of hardware, software and online services designed to cost-effectively detect Peripheral Artery Disease (P.A.D.) and Chronic Venous Insufficiency (CVI). Vascular specialists, primary care providers, hospitals and health systems use our products to identify these patients. Our devices and Health Information Technology (HIT) software reduce mistakes, provide data for sound analysis, build practice revenue and streamline reimbursement while providing a platform that supports the continuum of care and increased quality outcomes. For more information about BioMedix™ products, call 877-854-0014 or log on to www.BioMedix.com.

PADnet™ and TRAKnet™ are trademarks of BioMedix™

About APMA

Founded in 1912, the American Podiatric Medical Association (APMA) is the nation's leading and recognized professional organization for doctors of podiatric medicine (DPMs). DPMs are podiatric physicians and surgeons, also known as podiatrists, qualified by their education, training and experience to diagnose and treat conditions affecting the foot, ankle and structures of the leg. The medical education and training of a DPM includes four years of undergraduate education, four years of graduate education at an accredited podiatric medical college and two or three years of hospital residency training.  APMA has 53 state component locations across the United States and its territories, with a membership of close to 12,000 podiatrists.  All practicing APMA members are licensed by the state in which they practice podiatric medicine. For more information, visit www.apma.org.


'/>"/>
SOURCE BioMedix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Knee Pain? An Exclusive Study Engineers Cartilage to Match Patients Own Tissue
2. PARI Nebulizer & Compressor Used Exclusively in Inspires Phase 3 CF Trial
3. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
4. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
5. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
6. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
7. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
8. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
9. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
10. John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden
11. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology:
(Date:9/24/2017)... ... ... Millions of families and businesses worldwide depend on high quality water from ... water. However, well water can also become contaminated with bacteria and odors from flood ... The EPA does not regulate private drinking water wells. Many states and towns do ...
(Date:9/24/2017)... ... ... boy was walking home and feeling down about himself. He didn’t think he was good ... he can do whatever he wants to do if he puts his mind to it. ... God created him with special talents and gifts. We see his internal dialogue change. He ...
(Date:9/24/2017)... ... ... The Other Sheep”: the ceremonial laws of Moses and the Holy Law of God reexamined. ... author, Maurice Caines. Maurice Caines resides in the sunny isle of Florida, but he ... Adventist Church for many years. He was previously a member of the Anglican Church ...
(Date:9/23/2017)... San Francisco, CA (PRWEB) , ... September 23, 2017 , ... ... Bay Area, is proud to announce a new blog post focused on the ARTAS® ... loss, they understandably hope to turn to the latest, most technologically sophisticated methods of ...
(Date:9/22/2017)... Albert Lea, MN (PRWEB) , ... September 22, 2017 , ... ... and video) at its rally to interview citizens on why they are rallying against ... stories and commitment to this effort against Dr. Noseworthy’s (CEO) decision to close the ...
Breaking Medicine News(10 mins):